Search

Your search keyword '"Brodsky R"' showing total 228 results
Start Over Author "Brodsky R"
228 results on '"Brodsky R"'

1. Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.

Author

Asteris, PG, Gandomi, AH, Armaghani, DJ, Tsoukalas, MZ, Gavriilaki, E, Gerber, G, Konstantakatos, G, Skentou, AD, Triantafyllidis, L, Kotsiou, N, Braunstein, E, Chen, H, Brodsky, R, Touloumenidou, T, Sakellari, I, Alkayem, NF, Bardhan, A, Cao, M, Cavaleri, L, Formisano, A, Guney, D, Hasanipanah, M, Khandelwal, M, Mohammed, AS, Samui, P, Zhou, J, Terpos, E, Dimopoulos, MA, Asteris, PG, Gandomi, AH, Armaghani, DJ, Tsoukalas, MZ, Gavriilaki, E, Gerber, G, Konstantakatos, G, Skentou, AD, Triantafyllidis, L, Kotsiou, N, Braunstein, E, Chen, H, Brodsky, R, Touloumenidou, T, Sakellari, I, Alkayem, NF, Bardhan, A, Cao, M, Cavaleri, L, Formisano, A, Guney, D, Hasanipanah, M, Khandelwal, M, Mohammed, AS, Samui, P, Zhou, J, Terpos, E, and Dimopoulos, MA

Abstract

Complement inhibition has shown promise in various disorders, including COVID-19. A prediction tool including complement genetic variants is vital. This study aims to identify crucial complement-related variants and determine an optimal pattern for accurate disease outcome prediction. Genetic data from 204 COVID-19 patients hospitalized between April 2020 and April 2021 at three referral centres were analysed using an artificial intelligence-based algorithm to predict disease outcome (ICU vs. non-ICU admission). A recently introduced alpha-index identified the 30 most predictive genetic variants. DERGA algorithm, which employs multiple classification algorithms, determined the optimal pattern of these key variants, resulting in 97% accuracy for predicting disease outcome. Individual variations ranged from 40 to 161 variants per patient, with 977 total variants detected. This study demonstrates the utility of alpha-index in ranking a substantial number of genetic variants. This approach enables the implementation of well-established classification algorithms that effectively determine the relevance of genetic variants in predicting outcomes with high accuracy.

Published
2024

4. P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS

Author

Kulasekararaj, A., primary, Brodsky, R., additional, Griffin, M., additional, Kulagin, A., additional, Ogawa, M., additional, Wang, J., additional, Mujeebuddin, A., additional, Nishimura, J.-I., additional, Peffault de Latour, R., additional, Szer, J., additional, and Lee, J. W., additional

Published
2022
Full Text
View/download PDF

18. PS1529 CROSSTALK AMONG COMPLEMENT, COAGULATION AND NEUTROPHILS IN TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Author

Gavriilaki, E., primary, Chrysanthopoulou, A., additional, Sakellari, I., additional, Batsis, I., additional, Mallouri, D., additional, Touloumenidou, T., additional, Papalexandri, A., additional, Mitsios, A., additional, Koravou, E.-E., additional, Arampatzioglou, A., additional, Ritis, K., additional, Brodsky, R., additional, Mitroulis, I., additional, and Anagnostopoulos, A., additional

Published
2019
Full Text
View/download PDF

24. Viewpoint: The Time Has Come for the B.S. in Astronautical Engineering.

Author

Brodsky, R. F.

Abstract

Argues in favor of establishing an accreditable curriculum in "pure" astronautical engineering (leading to a bachelor of science degree in this field), giving reasons why such reform is needed (including equating "astronautics" with "aeronautics") and why a new curriculum is needed. (JN)

Published
1985

25. A New Type of Faculty Improvement Leave.

Author

Brodsky, R. F.

Abstract

An engineering professor tells of his experience in acquiring a leave of absence to work in industry for one year. He describes the projects with which he was involved, the salient features of the arrangement, the working conditions, and the positive results of the program. (SA)

Published
1979

26. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry

Author

Socie, G., Schrezenmeier, H., Muus, P., Lisukov, I., Roth, A., Kulasekararaj, A., Lee, J.W., Araten, D., Hill, A., Brodsky, R., Urbano-Ispizua, A., Szer, J., Wilson, A., and Hillmen, P.

Subjects
hemic and lymphatic diseases, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Medizin
Abstract

Item does not contain fulltext BACKGROUND: Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disease. Although much progress has been made in the understanding of the pathophysiology of the disease, far less is known with respect to the clinical outcomes of patients with PNH. Few retrospective studies provide survival estimates, and even fewer have explored the clinical heterogeneity of the disease. Haemolytic and aplastic anaemia (AA) forms of the disease have been recognised as main disease categories, with the haemolytic form being associated with the worst prognosis by the largest studied cohort some years ago. AIMS: To describe mortality and causes of death in PNH overall and by PNH classification and to evaluate risk factors associated with mortality. METHODS: We analysed data of 2356 patients enrolled in the International PNH Registry with multivariate analyses, using time-dependent covariates. Patients were classified into haemolytic, AA/PNH syndrome or intermediate PNH. RESULTS: Overall, 122 (5.2%) patients died after enrolment, the incidence according to subcategories being 5.1, 11.7, 2.0 and 4.8% for patients with haemolytic PNH, AA-PNH, intermediate and insufficient data respectively. Older age and decreased performance status also affected survival in multivariate analysis. Improved outcome of patients with haemolytic PNH suggests that eculizumab treatment in PNH may be associated with improved survival. CONCLUSION: A detailed analysis of clinical presentations and causes of death in patients with PNH, overall and by disease subcategories, provide evidence that in the current era, patients with haemolytic PNH are no longer those who harbour the worst prognosis. This finding differs sharply from what has been previously reported.

Published
2016

28. Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Author

Gladstone, D. E., Petri, M., Bolaños-Meade, J., Dezern, A. E., Jones, R. J., Fine, D., and Brodsky, R. A.

Subjects
SYSTEMIC lupus erythematosus diagnosis, SYSTEMIC lupus erythematosus, AUTOIMMUNE diseases, IMMUNE system, CYCLOPHOSPHAMIDE, PATIENTS
Abstract

Systemic lupus erythematosus (SLE), a disorder of the immune system, is potentially curable by allogeneic bone marrow transplantation (alloBMT). Until recently, alloBMT was limited by donor availability and toxicity. Reduced intensity conditioning (RIC) combined with posttransplantation cyclophosphamide (PTCy) has improved the availability and safety of alloBMT permitting its exploration in severe-refractory autoimmune illnesses. We report the six-year follow-up of a young female whose refractory SLE-associated nephrosis resolved after RIC alloBMT with PTCy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

29. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Author

Schrezenmeier, H., primary, Muus, P., additional, Socie, G., additional, Szer, J., additional, Urbano-Ispizua, A., additional, Maciejewski, J. P., additional, Brodsky, R. A., additional, Bessler, M., additional, Kanakura, Y., additional, Rosse, W., additional, Khursigara, G., additional, Bedrosian, C., additional, and Hillmen, P., additional

Published
2014
Full Text
View/download PDF

35. Earth orbiter into planetary orbiter - What's the problem?

Author

Brodsky, R. F

Subjects
Spacecraft Design, Testing And Performance
Abstract

A recent series of competitive design studies appears to have yielded positive results about the efficacy of adapting earth-orbiting spacecraft to perform planetary missions. The purpose of this paper is twofold: (1) to show the intrinsic attributes required to adapt an earth orbiter into a Martian orbiter compatible with the scientific requirements, and (2) to show the minimum requisite changes needed to make the adaptation. It is shown that major deficiencies of such conversion for earth-orbiting satellites lie in the not-unexpected inability of its telecommunications system to operate at Martian distances and its lack of an autonomous recovery system from anomalous performance. Since these deficiencies can be overcome without too great a financial or schedule penalty, the study shows that the adaptation can be made cost effectively.

Published
1984

37. A proposed university/industry/government cooperative aero educational program

Author

Brodsky, R. F

Subjects
Social Sciences (General)
Abstract

A program is proposed to provide mutual aid between the beleaguered Aero Engineering degree-granting departments in the United States and United States industry/government. It is proposed that any accrued cost differentials be supported by the latter groups, although all programs proposed will provide true mutual assistance. The program suggested is designed to provide assured industrial experience for Aero faculty members, combat engineering obsolescence for industry engineers, provide assured summer work for Aero undergraduates, encourage industry/government input in curriculum and course planning, and funnel significant laboratory devices into the university system.

Published
1975

38. Status review of liquid rocket static test range at Iowa State University

Author

Brodsky, R. F

Subjects
Ground Support Systems And Facilities (Space)
Abstract

The liquid rocket static test range of the Iowa State University incorporates an Aerobee sustainer propulsion system consisting of a pressure fed (helium) liquid bipropellant (hypergolic) rocket engine with a regeneratively fuel-cooled thrust chamber assembly. The paper covers test results to date (including results of four test firings in the water expulsion mode), construction details of the test stand, the laboratory course syllabus, and the environmental impact statement.

Published
1976

39. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen

Author

Bolaños-Meade, J, primary, Luznik, L, additional, Muth, M, additional, Matsui, W H, additional, Huff, C A, additional, Smith, B D, additional, Levy, M Y, additional, Kasamon, Y L, additional, Swinnen, L J, additional, Powell, J D, additional, Brodsky, R A, additional, Ambinder, R F, additional, Jones, R J, additional, and Fuchs, E J, additional

Published
2008
Full Text
View/download PDF

47. Accelerator Production of Tritium (APT)

Author

MITRE CORP MCLEAN VA JASON PROGRAM OFFICE, Drell, S., Briggs, R., Brodsky, R., Callan, C., Dietz, R. J., MITRE CORP MCLEAN VA JASON PROGRAM OFFICE, Drell, S., Briggs, R., Brodsky, R., Callan, C., and Dietz, R. J.

Abstract

There is continuing interest in Accelerator Production of Tritium (APT) because, the lack of uranium, plutonium, and fission product inventory; the low residual radioactivity and heat; the low operating temperature and pressure; and the ease of rapid shutdown suggest that an APT system is an attractive option in terms of safety, environmental impact, and public acceptance. The goal quantity of tritium production has been reduced to between three-eights and one-half that set previously; the date set for initiation of new tritium production has been delayed by five years from 2000 AD to 2005 AD; and, since February 1990, there have been advances in understanding the technology of both the accelerator and the target components of an APT system.

Published
1992

50. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures.

Author

Dussán, K. B., Magder, L., Brodsky, R. A., Jones, R. J., and Petri, M.

Subjects
SYSTEMIC lupus erythematosus, BIOMETRY, PHOSPHAMIDON, CENTRAL nervous system, CLINICAL trials, STEM cells
Abstract

In spite of current therapies, the overall health status of patients with SLE is poor. High-dose cyclophosphamide (50 mg/kg for 4 days) with or without stem-cell rescue has been introduced as a new therapy for severe SLE, including renal and central nervous system (CNS)-SLE. Long-term durable responses have been found to be 40%. A randomised clinical trial was completed comparing high-dose cyclophosphamide with monthly intravenous cyclophosphamide (750 mg/m squared bovine serum albumin) in patients with SLE who need cyclophosphamide for the first time. The primary outcome of the trial was complete clinical response. In this report, we compare the treatment groups with respect to quality of life. The patients in this study had a mean age of 35.3 ± 10.1 years, were of Caucasian (35%), African-American (51%), Hispanic (8%) and Asian (6%) people, and 88% were women. The organ leading to treatment was renal lupus in 29%, CNS-lupus in 45% and other organs in 26%. Quality of life was measured at each visit using the Medical Outcome Study Short-Form 36 (SF-36). At 6 months, the patients in the high-dose cyclophosphamide trial arm had significantly greater improvement than patients in the monthly intravenous cyclophosphamide arm (P = 0.026; P = 0.0082, respectively) in the categories of general health and social functioning. At 18 months, the improvement in the role-physical score was significantly greater in the high-dose cyclophosphamide trial arm than in the monthly-dose cyclophosphamide arm (P = 0.025). At the end of the two and a half-year study, there were no significant differences between the groups with respect to changes in SF-36. By pooling the groups, at 30 months, there was a statistically significant (P < 0.05) improvement over baseline in 6 of the 8 SF-36 domains. This study shows earlier improvement in SF-36 measures at 6 months in the high-dose cyclophosphamide group but equal improvement in both arms at two and one and a half years. Eventual improvements in quality-of-life with both cyclophosphamide regimens are clinically meaningful to both patients and treating physicians. [ABSTRACT FROM AUTHOR]

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results